



BLUEBERRIES MEDICAL CORP.

Notice of Annual General Meeting of Shareholders

To be held on October 7, 2022

Management Information Circular

August 25, 2022

Table of Contents

Notice of Annual General Meeting of Shareholders	1
MANAGEMENT INFORMATION CIRCULAR	3
General Information.....	3
VOTING INFORMATION.....	3
SOLICITATION OF PROXIES.....	3
APPOINTMENT AND REVOCATION OF PROXIES	3
VOTING OF PROXIES.....	4
NON-REGISTERED SHAREHOLDERS.....	4
APPROVAL OF RESOLUTIONS.....	5
INTEREST OF CERTAIN PERSONS OR COMPANIES IN MATTERS TO BE ACTED UPON	6
VOTING SECURITIES AND PRINCIPAL HOLDERS OF VOTING SECURITIES	6
BUSINESS OF THE MEETING	7
RECEIPT OF FINANCIAL STATEMENTS.....	7
ELECTION OF DIRECTORS	7
COMPENSATION OF EXECUTIVE OFFICERS.....	10
Statement of Executive Compensation	10
Stock Options and Other Compensation Securities.....	11
CORPORATE GOVERNANCE DISCLOSURE	15
AUDIT COMMITTEE INFORMATION.....	18
Audit Committee Charter.....	19
Composition of the Audit Committee	19
Relevant Education and Experience	19
Reliance on Certain Exemptions	20
Audit Committee Oversight	20
Pre-Approval Policies and Procedures.....	20
External Auditor Service Fees	20
INDEBTEDNESS OF DIRECTORS AND EXECUTIVE OFFICERS	20
INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS	20
MANAGEMENT CONTRACTS	21
ADDITIONAL INFORMATION.....	21
ADDITIONAL BUSINESS	21
APPROVAL OF INFORMATION CIRCULAR	21

Appendices

Schedule 'A' – Mandate of the Board of Blueberries Medical Corp.

Schedule 'B' – Audit Committee Charter.

Blueberries Medical Corp.
NOTICE OF ANNUAL GENERAL MEETING
OF SHAREHOLDERS

TAKE NOTICE that the Annual General Meeting (the “**Meeting**”) of the shareholders of Blueberries Medical Corp. (the “**Company**”) will be on October 7, 2022 at 1:00 PM Eastern Time as a **virtual-only meeting**. The following are the purposes of the Meeting:

1. To receive the audited consolidated financial statements of the Company for the year ended December 31, 2021, together with the auditor’s report thereon;
2. To set the number of Directors of the Company at five;
3. To elect Directors for the ensuing year;
4. To appoint MNP LLP, Chartered Professional Accountants as auditors for the Company for the ensuing year and to authorize the board of directors to fix their remuneration; and
5. To transact such other business as may properly come before the Meeting, or at any adjournment thereof.

The Company is holding the Meeting as a completely virtual meeting, where all shareholders regardless of geographic location and equity ownership will have an equal opportunity to participate at the Meeting. Shareholders will not be able to attend the Meeting in person. The Meeting can be accessed via the following Microsoft Teams meeting link:

https://teams.microsoft.com/l/meetup-join/19%3ameeting_NzFhMDkzOGItNzI3MC00MDYxLTkyYTAAtNjY0NjRhNmU1Nzd%40thread.v2/0?context=%7b%22Tid%22%3a%221a610d8-3619-4fd0-81e0-45da84ca2a69%22%2c%22Oid%22%3a%224616b0c6-327d-4d0c-b9b8-641624cb58ca%22%7d

Meeting ID: 218 328 175 71

Passcode: KotVe9

Shareholders of record at the close of business August 25th, 2022 will be entitled to receive notice, attend and vote at the Meeting. As a shareholder of the Company, it is very important that you read the management information circular of the Company dated August 25, 2022 (the “Circular”) and other Meeting materials carefully. They contain important information with respect to voting your Shares and attending and participating at the Meeting.

Registered shareholders and duly appointed proxyholders will be able to attend, ask questions and vote at the Meeting online. Non-registered shareholders (being shareholders who beneficially own shares that are registered in the name of an intermediary such as a bank, trust company, securities broker or other nominee, or in the name of a depository of which the intermediary is a participant) who have not duly appointed themselves as proxyholder will be able to attend the Meeting online as guests, but guests will not be able to vote or ask questions at the Meeting.

Specific details of the above items of business are contained in the Information Circular of management which accompanies this Notice of Meeting (the “**Notice**”) and, together with management’s Instrument of Proxy (“**Proxy**”) or Voting Instruction Form (“**VIF**”) which also accompanies the Notice, form a part hereof and must be read in conjunction with this Notice.

If you are unable to attend the Meeting, please read the Instructions For Completion of Proxy (“**Instructions**”) on the reverse side of the Proxy or Instructions For Completion of VIF (“**VIF Instructions**”) enclosed herewith and then complete and return the Proxy or VIF within the time set out in the Instructions or VIF Instructions as the case may be. In addition, as set out in the Instructions and VIF Instructions, the enclosed Proxy or VIF is solicited by management of the Company but you may amend it if you so desire by striking out the names listed therein and inserting in the space provided the name of the person you wish to represent you at the Meeting.

DATED at Toronto, Ontario, this 25th day of August 2022.

BY ORDER OF THE BOARD OF DIRECTORS – Blueberries Medical Corp.

“Guillermo Pablo Rodriguez”
Chief Financial Officer

Shareholders are cordially invited to attend the Meeting. Shareholders are urged to complete and return the enclosed proxy or VIF promptly. To be effective, Blueberries proxies must be received at the Toronto office of Computershare Investor Services Inc. (“**Computershare**”), the Company’s registrar and transfer agent, by 1:00 p.m. (Eastern Time) on October 5, 2022, or 48 hours (excluding Sundays, Saturdays and holidays) prior to any adjourned Meeting. A proxy will not be valid unless it is deposited with Computershare, (i) by mail using the enclosed return envelope or (ii) by hand delivery to Computershare, 8th Floor, 100 University Avenue, Toronto, Ontario, M5J 2Y1. Alternatively, you may vote by telephone at 1-866-732-VOTE (8683) (toll free within North America) or 1-312-588-4290 (outside North America), by facsimile to 1-866-249-7775 or 1-416-263-9524 (if outside North America), or by internet using the 15-digit control number located at the bottom of your proxy at www.investorvote.com. All instructions are listed in the enclosed form of proxy.

Shareholders whose Common Shares are held by a nominee may receive either a VIF or form of Proxy and should follow the instructions provided by the nominee. Proxies will be counted and tabulated by Computershare in such a manner as to protect the confidentiality of how a particular Shareholder votes except where they contain comments clearly intended for management, in the case of a proxy contest, or where it is necessary to determine the validity of a Proxy or to permit management and the Board to discharge their legal obligations to the Company or its Shareholders.

MANAGEMENT INFORMATION CIRCULAR

for the Annual General Meeting of Shareholders

General Information

Except as otherwise stated, the information contained herein is given as of August 25, 2022.

Figures in this Circular are expressed in Canadian dollars (“\$” or “C\$”), the same currency that Blueberries Medical Corp. (“Blueberries”, or the “Company”) uses in its consolidated financial statements for the year ended December 31, 2021 (the “Annual Financial Statements”), unless otherwise stated.

VOTING INFORMATION

SOLICITATION OF PROXIES

THIS INFORMATION CIRCULAR (THE “CIRCULAR”) IS FURNISHED IN CONNECTION WITH THE SOLICITATION OF PROXIES BY THE MANAGEMENT OF THE COMPANY FOR USE AT THE ANNUAL GENERAL MEETING (THE “MEETING”) OF THE COMPANY TO BE HELD ON FRIDAY, OCTOBER 7, 2022, OR ANY ADJOURNMENTS THEREOF, FOR THE PURPOSES SET FORTH IN THE ACCOMPANYING NOTICE OF MEETING.

This year, the Meeting will be held in a virtual only format. Shareholders and duly appointed proxyholders can attend the Meeting via the following Microsoft Teams meeting link:

https://teams.microsoft.com/l/meetup-join/19%3ameeting_NzFhMDkzOGItNzI3MC00MDYxLTkyYtAtNjY0NjRhNmU1Nzdh%40thread.v2/0?context=%7b%22Tid%22%3a%221a610d8-3619-4fd0-81e0-45da84ca2a69%22%2c%22Oid%22%3a%224616b0c6-327d-4d0c-b9b8-641624cb58ca%22%7d

Meeting ID: 218 328 175 71

Passcode: KotVe9

While it is expected that the solicitation will be primarily by mail, proxies may be solicited personally or by telephone by the directors, officers and regular employees of the Company at nominal cost. All costs of solicitation of proxies by management will be borne by the Company.

Meeting Materials can be accessed directly online at <http://www.blueberriesmed.com>

Notice to Shareholders in the United States

The solicitation of proxies involves securities of an issuer located in Canada and is being affected and disclosed in accordance with securities laws of the provinces of Canada. Shareholders should be aware that disclosure requirements under the securities laws of the provinces of Canada differ from the disclosure requirements under United States securities laws.

APPOINTMENT AND REVOCATION OF PROXIES

THE PERSONS NAMED IN THE ACCOMPANYING INSTRUMENT OF PROXY ARE OFFICERS OF THE COMPANY. A SHAREHOLDER DESIRING TO APPOINT SOME OTHER PERSON (WHO NEED NOT BE A SHAREHOLDER) TO ATTEND AND ACT ON THE SHAREHOLDER’S BEHALF AT THE MEETING HAS THE RIGHT TO DO SO, EITHER BY STRIKING OUT THE NAMES OF THOSE PERSONS NAMED IN THE ACCOMPANYING INSTRUMENT OF PROXY AND INSERTING THE DESIRED PERSON’S NAME IN THE BLANK SPACE PROVIDED IN THE INSTRUMENT OF PROXY, OR BY COMPLETING ANOTHER INSTRUMENT OF PROXY.

AN INSTRUMENT OF PROXY MUST BE IN WRITING AND SIGNED BY THE SHAREHOLDER OR BY THE SHAREHOLDER’S ATTORNEY DULY AUTHORIZED IN WRITING OR, IF THE SHAREHOLDER IS A CORPORATION, SIGNED BY A DULY AUTHORIZED OFFICER OR ATTORNEY OF THE COMPANY. IF THE PROXY IS TO APPLY TO LESS THAN ALL THE COMMON SHARES REGISTERED IN THE NAME OF THE SHAREHOLDER, THE PROXY MUST SPECIFY THE NUMBER OF COMMON SHARES TO WHICH IT APPLIES. A PROXY WILL NOT BE VALID UNLESS THE COMPLETED INSTRUMENT OF PROXY AND THE POWER OF ATTORNEY OR OTHER AUTHORITY, IF ANY, UNDER WHICH IT IS SIGNED, OR A NOTARIALY CERTIFIED COPY THEREOF SATISFACTORY TO THE COMPANY, IS RECEIVED BY COMPUTERSHARE INVESTOR SERVICES INC. (“COMPUTERSHARE”), PROXY DEPARTMENT, 8TH FLOOR, 100 UNIVERSITY AVENUE, TORONTO, ONTARIO, M5J 2Y1. ALTERNATIVELY, YOU MAY VOTE BY TELEPHONE AT 1-866-732-VOTE (8683) (toll free within North America) or 1-312-588-4290 (outside North America), BY FACSIMILE TO 1-866-249-7775 OR 1-416-263-9524 (if outside North America), OR

BY INTERNET USING THE 15 DIGIT CONTROL NUMBER LOCATED AT THE BOTTOM OF YOUR PROXY AT www.investorvote.com NOT LESS THAN 48 HOURS (EXCLUDING SATURDAYS, SUNDAYS AND HOLIDAYS) BEFORE THE COMMENCEMENT OF THE MEETING, OR ANY ADJOURNMENT THEREOF.

A shareholder who has been given an Instrument of Proxy may revoke it by an instrument in writing signed by the shareholder or by the Shareholder's attorney authorized in writing or, where the Shareholder is a corporation by a duly authorized officer or attorney of the Company, and delivered to the administrative offices of the Company, 82 Richmond Street East, Toronto, Ontario, Canada M5C 1P1, at any time up to and including the last business day preceding the day of the Meeting, or any adjournment thereof at which the Instrument of Proxy is to be used, or to the Chair of the Meeting on the day of the Meeting or any adjournment thereof or in any other manner provided by law. A revocation of an Instrument of Proxy does not affect any matter on which a vote has been taken prior to the revocation.

VOTING OF PROXIES

THE MANAGEMENT REPRESENTATIVES DESIGNATED IN THE ENCLOSED INSTRUMENT OF PROXY WILL VOTE OR WITHHOLD FROM VOTING THE COMMON SHARES IN RESPECT OF WHICH THEY ARE APPOINTED PROXY ON ANY POLL THAT MAY BE CALLED FOR IN ACCORDANCE WITH THE INSTRUCTIONS OF THE SHAREHOLDER AS INDICATED ON THE INSTRUMENT OF PROXY AND, IF THE SHAREHOLDER SPECIFIES A CHOICE WITH RESPECT TO ANY MATTER TO BE ACTED UPON, THE COMMON SHARES WILL BE VOTED ACCORDINGLY. WHERE NO CHOICE OR WHERE BOTH CHOICES ARE SPECIFIED IN THE INSTRUMENT OF PROXY, SUCH COMMON SHARES WILL BE VOTED "FOR" THE MATTERS OR PERSONS DESCRIBED THEREIN AND IN THIS INFORMATION CIRCULAR.

The enclosed Instrument of Proxy confers discretionary authority upon the person appointed proxy thereunder to vote with respect to amendments or variations of matters identified in the Notice of Meeting and with respect to other matters that may properly come before the Meeting. In the event that amendments or variations to matters identified in the Notice of Meeting are properly brought before the Meeting or any other business is properly brought before the Meeting, the persons designated in the enclosed Instrument of Proxy will vote in accordance with their best judgment on such matters or business. At the time of the printing of this Circular, management of the Company knows of no such amendments, variations or other matters which may be presented to the Meeting.

NON-REGISTERED SHAREHOLDERS

Only registered Shareholders or their duly appointed proxy holders are permitted to vote at the Meeting. Most Shareholders are "non-registered" Shareholders because the Common Shares they own are not registered in their names but are instead registered in the name of the brokerage firm, bank or trust company through which they purchased the Common Shares or a clearing agency. More particularly, a person is not a registered Shareholder in respect of Common Shares which are held on behalf of that person (the "**Non-Registered Holder**") but which are registered either: (a) in the name of an intermediary (an "**Intermediary**") that the Non-Registered Holder deals with in respect of the Common Shares (Intermediaries include, among others, banks, trust companies, securities dealers or brokers and trustees or administrators of self-administered RRSPs, RRFs, RESPs and similar plans); or (b) in the name of a clearing agency (such as the Canadian Depository for Securities Limited ("**CDS**")) of which the Intermediary is a participant. In accordance with the requirements of National Instrument 54-102, the Company has distributed copies of the Notice of Meeting, this Information Circular and the Instrument of Proxy (collectively, the "**Meeting Materials**") to the clearing agencies and Intermediaries for onward distribution to Non-Registered Holders.

Intermediaries are required to forward the Meeting Materials to Non-Registered Holders unless a Non-Registered Holder has waived the right to receive them. Very often, Intermediaries will use service companies to forward the Meeting Materials to Non-Registered Holders. Generally, Non-Registered Holders who have not waived the right to receive Meeting Materials will either:

- a) be given an Instrument of Proxy which has already been signed by the Intermediary (typically by a facsimile, stamped signature), which is restricted as to the number of Common Shares beneficially owned by the Non-Registered Holder but which is otherwise not completed. Because the Intermediary has already signed the Instrument of Proxy, this Instrument of Proxy is not required to be signed by the Non-Registered Holder when submitting the Instrument of Proxy. In this case, the Non-Registered Holder who wishes to submit an instrument of proxy should otherwise properly complete the Instrument of Proxy and deposit it with the Company as provided above; or
- b) more typically, be given a Voting Instructions Form (a "**VIF**") which is not signed by the Intermediary, and which, when properly completed and signed by the Non-Registered Holder and returned to the Intermediary or its service company, will constitute voting instructions (often called a "**proxy authorization form**") which the Intermediary must follow.

Typically, the proxy authorization form will consist of a one-page, pre-printed form. Sometimes, instead of the one-page, pre-printed form, the proxy authorization form will consist of a regular printed proxy form accompanied by a page of instructions which contains a removable label containing a bar-code and other information. In order for the Instrument of Proxy to validly constitute a proxy authorization form, the Non-Registered Holder must remove the label from the instructions and affix it to the Instrument of Proxy, properly complete and sign the Instrument of Proxy and return it to the Intermediary or its service company in accordance with the instructions of the Intermediary or its service company. Every intermediary/broker has its own mailing procedures and provides its own return instructions to clients, which should be carefully followed by Beneficial Shareholders in order to ensure that their common shares are voted at the Meeting.

In either case, the purpose of this procedure is to permit Non-Registered Holders to direct the voting of the Common Shares which they beneficially own. Should a Non-Registered Holder who receives one of the above forms wish to vote at the Meeting in person, the Non-Registered Holder should strike out the names of the management's representatives named in the Instrument of Proxy and insert the Non-Registered Holder's name in the blank space provided. In either case, Non-Registered Holders should carefully follow the instructions of their Intermediary, including those regarding when and where the instrument of proxy or proxy authorization form is to be delivered.

All reference to shareholders in this Information Circular and the accompanying Instrument of Proxy and Notice of Meeting are to shareholders of record unless specifically stated otherwise. In addition, there are two kinds of Beneficial Owners – those who object to their names being made known to the issuers of securities which they own being called Objecting Beneficial Owners (“**OBOs**”) and those who do not object to the issuers of the securities knowing who they are being called Non-Objecting Beneficial Owners (“**NOBOs**”).

The Company will avail itself of those provisions of National Instrument 54-101, *Communication with Beneficial Owners of Securities of Reporting Issuers* (“**NI 54-101**”) that permit it to directly deliver proxy related materials to its NOBOs. As a result, NOBOs can expect to receive a scannable Request for a VIF from Blueberries' transfer agent, Computershare. These VIFs are to be completed and returned to Computershare in the envelope provided or by facsimile. Computershare will tabulate the results of the VIFs received from NOBOs and will provide appropriate instructions at the Meeting with respect to the Common Shares represented by the VIFs they receive.

APPROVAL OF RESOLUTIONS

Unless otherwise specified, a simple majority of affirmative votes cast at the Meeting is required to pass the resolutions described herein. If there are more nominees for election as directors or appointment as the Company's auditor than there are vacancies to fill, those nominees receiving the greatest number of votes will be elected or appointed, as the case may be, until all such vacancies have been filled. If the number of nominees for election or appointment is equal to the number of vacancies to be filled, all such nominees will be declared elected or appointed by acclamation.

INTEREST OF CERTAIN PERSONS OR COMPANIES IN MATTERS TO BE ACTED UPON

None of the directors or senior officers of the Company, no management nominee for election as a director of the Company, none of the persons who have been directors or senior officers of the Company since the commencement of the Company's last completed financial year, and no associate or affiliate of any of the foregoing, has any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter to be acted upon at the Meeting other than as disclosed elsewhere herein.

VOTING SECURITIES AND PRINCIPAL HOLDERS OF VOTING SECURITIES

The Company has fixed the close of business on August 25, 2022 (the "Record Date") as the record date. Only those holders of record of Common Shares on August 25, 2022, are entitled to vote at the Meeting. As at the close of business on August 25, 2022, 163,810,263 Common Shares were issued and outstanding. Each Common Share carries the right to one vote at the Meeting. There are no other classes of voting securities outstanding.

Shareholders whose names have been entered in the register of Shareholders at the close of business on the Record Date will be entitled to receive notice of, and to vote, at the Meeting or any adjournments or postponements thereof. Persons registered on the books of the Company at the close of business on the Record Date and persons who are transferees of any Common Shares acquired after the Record Date and who have produced properly endorsed certificates evidencing such Common Shares or who otherwise establish ownership thereof and demand, not later than 10 days before the Meeting, that their names be included in the list of Shareholders, are entitled to vote at the Meeting.

To the knowledge of the directors or senior officers of the Company, as at the date of this Circular, no person or company beneficially owns, directly or indirectly, or exercises control or direction over, 10% or more of the Common Shares, except the following:

Name of shareholder	Number of Common Shares Held	Percentage of Common Shares Outstanding
Terraflos Inc. ⁽¹⁾	32,035,094 ⁽²⁾	19.56%

⁽¹⁾ Terraflos Inc. is a company controlled by Facundo Garretón, the Company's Executive Chairman, Director and Chief Executive Officer.

⁽²⁾ This information was not provided directly by the insider.

In aggregate, including those held by the Named Executive Officers, the directors and other officers of the Company hold 34,925,951 Common Shares, representing 21.32% of the issued Common Shares.

BUSINESS OF THE MEETING

RECEIPT OF FINANCIAL STATEMENTS

The Annual Financial Statements and accompanying auditor's report thereon will be presented at the Meeting and will be mailed to those registered and beneficial Shareholders who requested them. The Annual Financial Statements are available under the Company's profile on the System for Electronic Document Analysis and Retrieval ("SEDAR") at www.sedar.com and at www.blueberriesmed.com.

ELECTION OF DIRECTORS

On January 20, 2021, in connection with the completion of a strategic financing led by FLA Ventures Ltd., Christian Toro resigned as Chairman and Chief Executive Officer of the Company and was replaced by Facundo Garretón. Previous directors Christian Toro, Fabio Valencia Cossio, Dr. Andres Vidal, Francisco Sole, and Paola Castañeda all resigned from the Board effective January 20, 2021. The Board is currently comprised of the following five directors: Facundo Garretón, Patricio Villalba, Catherine Lathwell, Sebastian Hochbaum and Joaquin Barbera.

The Company's by-laws provide that the Board shall consist of such number of directors as may be fixed from time to time by resolution of the Board. The Board currently consists of five (5) directors.

At the Meeting, the Shareholders will be asked to consider, and, if thought fit, approve with or without variation a resolution re-electing the five (5) current members of the Board as the directors of the Company, namely Facundo Garretón, Sebastian Hochbaum, Patricio Villalba, Catherine Lathwell and Joaquin Barbera. It is intended that each of the directors shall hold office until his successor is elected or appointed, unless his office is earlier vacated in accordance with the Articles of Incorporation of the Company, or with the provisions of BCABC, S.B.C. 2002, c. 57, as may be amended or replaced from time to time, including the regulations promulgated thereunder.

Shareholders have the option to (i) vote for all of the directors of the Company listed in the table below; (ii) vote for some of the directors and withhold for others; or (iii) withhold for all of the directors.

UNLESS OTHERWISE INSTRUCTED, PROXIES AND VOTING INSTRUCTIONS GIVEN PURSUANT TO THIS SOLICITATION BY THE MANAGEMENT OF THE COMPANY WILL BE VOTED FOR THE ELECTION OF EACH OF THE PROPOSED NOMINEES SET FORTH IN THE TABLE BELOW.

Management has no reason to believe that any of the nominees will be unable to serve as a director. However, if any proposed nominee is unable to serve as a director, the individuals named in the enclosed form of proxy will be voted in favour of the remaining nominees and may be voted in favour of a substitute nominee unless the Shareholder has specified in the proxy that the Common Shares represented thereby are to be withheld from voting in respect of the election of directors.

MAJORITY VOTING FOR DIRECTORS

The Board adopted a policy requiring that in an uncontested election of directors, any nominee who receives a greater number of votes "withheld" than votes "for" will tender a resignation to the Chair of the Board promptly following the Meeting. The Corporate Governance and Nominating Committee ("CGNC") will consider the offer of resignation and, except in special circumstances, will recommend that the Board accept the resignation. The Board will make its decision and announce it in a press release within 90 days following the Meeting, including the reasons for rejecting the resignation, if applicable. The nominee will not participate in any CGNC or Board deliberations on the resignation offer. The policy does not apply in circumstances involving contested director elections.

The following table states the name of each person nominated by management for election as directors, such person's principal occupation or employment, and the approximate number of voting securities and other (non-voting) equity instruments of the Company that such person beneficially owns, or over which such person exercises direction or control as of the date of this Circular:

Nominee & Ordinary Place of Residence	Position Held with Blueberries and Principal Occupation for the Past Five Years ⁽⁴⁾	Number of Common Shares Beneficially Owned	Number of Options Beneficially held ⁽⁶⁾
Facundo Garretón ⁽¹⁾ ⁽²⁾⁽³⁾ Age: 48 Punta Ballena, Maldonado, Uruguay	Director, Executive Chairman, Chief Executive Officer of Blueberries Director, Terraflos Inc. Former Member of Congress Honorable Cámara de Diputados de la Nación Argentina December 2015 – December 2019 Former CEO and Founder of Invertir Online Jan 2000 – November 2014 YPO – Regional Chairman 2010-2013	33,249,687 ⁽⁵⁾	2,750,000
Sebastian Hochbaum Age: 28 Buenos Aires, Argentina	Independent Director of Blueberries Director de Nuevos Negocios Control Media S.A. 2019-current Lawyer at Salaverri Burgio Wetzler Malbran Abogados 2018-2019 Pampa Energia – Lawyer 2017-2018	Nil	500,000
Catherine Lathwell CPA, CGA ⁽¹⁾ ⁽²⁾⁽³⁾ Age: 57 Toronto, Canada	Independent Director of Blueberries Accountant, PowerOne Capital Markets Limited (October 2015 to May 2018) Principal, Impresario Accounting (June 2018 to present) Chief Financial Officer and Corporate Secretary of White Gold Corp. (July 2020 to present)	Nil	205,000
Patricio Villalba ⁽¹⁾⁽²⁾⁽³⁾ Age: 47 Bogota, Colombia	Independent Director of Blueberries Stratus Energy Corp. President, (March 2014 to present)	300,000	630,000
Joaquin Barbera Age: 31 Mendoza, Argentina	Independent Director of Blueberries Co-founder and President of Grupo Broda Director of Sistema B Argentina	Nil	Nil

(1) Member of Audit Committee Catherine Lathwell (chair), Patricio Villalba and Facundo Garretón

(2) Member of Compensation Committee Patricio Villalba (chair), Catherine Lathwell and Facundo Garretón

(3) Member of Corporate Governance & Nominating Committee Patricio Villalba (chair), Catherine Lathwell and Facundo Garretón

(4) Information about principal occupation, business or employment and securities beneficially owned, directly or indirectly, or over which control or direction is exercised, has been furnished by respective persons set forth above.

(5) A total of 32,035,094 common shares were held by Terraflos Inc., a company that is controlled by Facundo Garretón.

(6) A total of 2,216,667 of stock options to purchase Common Shares ("**Options**") held are exercisable as of the date of this Circular. See also Stock Options and Other Compensation Securities in this Circular.

CORPORATION CEASE TRADE ORDER, BANKRUPTCY, PENALTIES AND SANCTIONS

As of the date of this Circular: (a) no proposed director of the Company is, or has been, within 10 years before the date of this Circular, a director, chief executive officer or chief financial officer of any company (including the Company) that, (i) was subject to a cease trade order, an order similar to a cease trade order, or an order that denied the relevant company access to any exemption under securities legislation, in each case in effect for a period of more than 30 consecutive days (each an "**order**") that was issued while the proposed director was acting in the capacity as director, chief executive officer or chief financial officer; or (ii) was subject to an order that was issued after the proposed director ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity as director, chief executive officer or chief financial officer; (b) no proposed director of the Company is, or has been within 10 years before the date of this Circular, a director or executive officer of any company (including the Company) that, while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets; (c) no proposed director of the Company has, within the 10 years before the date of this Circular, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or became subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to

hold the assets of the director, officer or shareholder; and (d) no proposed director of the Company has been subject to: (i) any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority; or (ii) any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable Shareholder in deciding whether to vote for a proposed director. To the knowledge of the Company, no personal holding company of any proposed director is or has been, as applicable, subject to the foregoing during the applicable time periods.

APPOINTMENT OF AUDITOR

At the Meeting, Shareholders will be asked to vote for the reappointment of MNP LLP, Chartered Professional Accountants (“**MNP**”), the current independent registered certified auditors of the Company, as the auditors of the Company to hold office until the close of the next annual meeting of Shareholders and to authorize the directors to fix their remuneration. A simple majority of the votes cast at the Meeting must be voted in favour thereof. MNP was first appointed auditor of the Company on January 9, 2019.

Unless such authority is withheld, the management proxy nominees named in the accompanying Proxy intend to vote “for” the appointment of MNP as auditors of the Company to hold office until the close of the next annual meeting of Shareholders and to authorize the directors to fix their remuneration.

UNLESS THE SHAREHOLDER HAS SPECIFICALLY INSTRUCTED IN THE ENCLOSED FORM OF PROXY THAT THE COMMON SHARES REPRESENTED BY SUCH PROXY ARE TO BE WITHHELD OR VOTED OTHERWISE, THE PERSONS NAMED IN THE ACCOMPANYING PROXY WILL VOTE FOR THE APPOINTMENT AND RATIFICATION OF MNP AS AUDITORS OF THE COMPANY TO HOLD OFFICE UNTIL THE NEXT ANNUAL MEETING OF SHAREHOLDERS OR UNTIL A SUCCESSOR IS APPOINTED AND TO AUTHORIZE THE BOARD TO FIX THE REMUNERATION OF THE AUDITORS.

COMPENSATION OF EXECUTIVE OFFICERS

Form 51-102F6V Disclosure

Statement of Executive Compensation

Executive Compensation

In this section “**Named Executive Officer**”, or “**NEO**”, means the Chief Executive Officer, the Chief Financial Officer and each of the three most highly compensated executive officers, other than the Chief Executive Officer and the Chief Financial Officer, who were serving as executive officers at the end of the most recently completed fiscal years of December 31, 2021, and December 31, 2020, and the most highly compensated executive officer other than the CEO or CFO whose total salary and bonus exceeded \$150,000, as well as any additional individuals for whom disclosure would have been provided except that the individual was not serving as an officer of the Company at the end of the most recently completed financial year end. For the year ended December 31, 2021, the NEOs were Messrs. Facundo Garretón, Guillermo Rodriguez, José Maria Forero, Christian Toro and Ian Atacan.

The following table sets for all direct and indirect compensation paid, payable, awarded, granted, given or otherwise provided, directly or indirectly, by the Company any subsidiary thereof to each Named Executive Officer and each director of the Company, in any capacity, including, for greater certainty, all plan and non-plan compensation, direct and in-direct pay, remuneration, economic or financial award, reward, benefit, gift or perquisite paid, payable, awarded, granted, given or otherwise provided to the Named Executive Officers or director for services provided and for services to be provided, directly or indirectly, to the Company or any subsidiary thereof:

Table of compensation

Name and position	Year	Salary (\$)	Share Based Awards (\$)	Option Based Awards ⁽⁵⁾⁽⁶⁾ (\$)	Non-equity Incentive Plan Compensation (\$)	All other compensation (\$)	Total compensation (\$)
Facundo Garretón ⁽¹⁾ Chief Executive Officer and Executive Chairman	2021	-	32,500 ⁽⁷⁾	105,433	-	-	137,933
	2020	-	-	-	-	-	-
Christian Toro ⁽²⁾ Former Chief Executive Officer and Executive Chairman	2021	-	-	-	-	-	-
	2020	65,000	-	93,815	-	-	158,815
Camilo Villalba ⁽³⁾ Former Chief Executive Officer	2021	-	-	-	-	-	-
	2020	123,261	-	118,725	-	-	241,986
Guillermo Rodriguez Chief Financial Officer	2021	-	-	13,738	-	-	13,738
	2020	-	-	-	-	-	-
Ian D. Atacan ⁽⁴⁾ Former Chief Financial Officer	2021	-	-	-	-	114,200	114,200
	2020	-	-	88,443	-	228,000	316,443
José Maria Forero President of Latin America Operations	2021	104,429	-	29,898	-	-	134,327
	2020	-	-	-	-	-	-

⁽¹⁾ Mr. Garretón was appointed as Chief Executive Officer and Executive Chairman on January 20, 2021.

⁽²⁾ Mr. Toro served as Chief Executive Officer between September 2018 and April 2019, at which time he was appointed Executive Chairman of the Board, and also served as Chief Executive Officer from October 23, 2020 to January 20, 2021. Mr. Toro resigned as Chief Executive Officer and Executive Chairman of the Board on January 20, 2021 and was replaced by Mr. Facundo Garretón.

⁽³⁾ Mr. Villalba served as Chief Operating Officer between September 1, 2018 and December 16, 2019 at which time he was appointed Chief Executive Officer. Mr. Villalba resigned as Chief Executive Officer of the Company on October 23, 2020 and was replaced by Mr. Christian Toro.

⁽⁴⁾ Mr. Atacan was appointed as Chief Financial Officer on June 24, 2019. Mr. Atacan resigned as Chief Financial Officer of the Company on May 31, 2021 and was replaced by Mr. Guillermo Rodriguez on June 1, 2021.

⁽⁵⁾ The Black-Scholes option valuation method is used to calculate the fair value of option-based awards on the grant date. The following assumptions were used to determine the value of granted options during 2021: expected dividend yield of 0%, risk free interest rate of 0.33% to 0.372%, expected volatility of 113% to 114%, a forfeiture rate of 0% and five year expected life. And during 2020: expected dividend yield of 0%, risk free interest rate of 0.59% to 1.57%, expected volatility of 85% to 89%, a forfeiture rate of 10% and three year expected life.

⁽⁶⁾ All options granted during 2021 are vesting one-third each on every one-year anniversary from the grant date.

⁽⁷⁾ A total of 250,000 common shares were issued to Mr. Garretón, which were valued at \$32,500 determined based on the share price of the Company on January 19, 2021.

Stock Options and Other Compensation Securities

Exercise of Compensation Securities (Options)

The following tables set out information concerning all equity-based awards held by each director and NEO that were outstanding as at December 30, 2021.

Stock Options

Name and position	Number of compensation securities, number of underlying securities, and percentage of class	Date of issue or grant ⁽¹⁾	Issue, conversion or exercise price (\$)	Closing price of security or underlying security on date of grant (\$)	Closing price of security or underlying security at year end (\$)	Expiry date
Facundo Garretón Chief Executive Officer and Executive Chairman	1,750,000	January 19, 2021	0.13	0.13	0.07	January 19, 2026
Christian Toro Former Chief Executive Officer and Executive Director	666,667	February 5, 2019	0.40	0.25 ⁽¹⁾	0.07	February 5, 2024
	300,000	March 27, 2020	0.10	0.15	0.07	March 27, 2025
Catherine Lathwell Director	75,000	February 5, 2019	0.40	0.25 ⁽¹⁾	0.07	February 5, 2024
	130,000	March 27, 2020	0.10	0.15	0.07	March 27, 2025
Patricio Villalba Director	500,000	February 5, 2019	0.40	0.25 ⁽¹⁾	0.07	February 5, 2024
	130,000	March 27, 2020	0.10	0.15	0.07	March 27, 2025
Sebastian Hochbaum Director	500,000	January 19, 2021	0.13	0.13	0.07	January 19, 2026
Paola Casteñeda Former Director	266,667	February 5, 2019	0.40	0.25 ⁽¹⁾	0.07	February 5, 2024
	130,000	March 27, 2020	0.10	0.15	0.07	March 27, 2025
Francisco Sole Former Director	333,334	February 5, 2019	0.40	0.25 ⁽¹⁾	0.07	February 5, 2024
	130,000	March 27, 2020	0.10	0.15	0.07	March 27, 2025
Fabio Valencia Former Director	333,334	March 18, 2019	0.55	0.55	0.07	March 19, 2024
	130,000	March 27, 2020	0.10	0.15	0.07	March 27, 2025
Andres Vidal Former Director	200,000	February 5, 2019	0.40	0.25 ⁽¹⁾	0.07	February 5, 2024
	130,000	March 27, 2020	0.10	0.15	0.07	March 27, 2025
Guillermo Rodriguez Chief Financial Officer	500,000	June 2, 2021	0.125	0.10	0.07	June 2, 2026
José María Forero President of Latin America Operations	500,000	February 3, 2021	0.135	0.135	0.07	February 3, 2026

(1) Options granted as part of the Transaction on February 5, 2019 being above the \$0.25 price at which the common shares of the Company were sold in the Company's last financing and the price that the directors of the Company determined constituted Fair Market Value.

Exercise of Compensation Securities (Options)

During December 31, 2021, Ian Atacan, former Chief Financial Officer, exercised 400,000 options, at the exercise price of \$0.10 per option, into 400,000 common shares.

Securities Authorized for Issuance Under Equity Compensation Plans

The following table provides details of compensation plans under which equity securities of the Company are authorized for issuance as of December 31, 2021. A description of the significant terms of each of the Company's equity compensation plans follows the table below:

Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants and rights (a)	Weighted-average exercise price of outstanding options, warrants and rights (b)	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
Equity compensation plans approved by security holders	7,510,001 Options	\$0.23/Option	8,871,024
Equity compensation plans not approved by security holders	Nil	Nil	Nil
Total	7,510,001 Options ⁽¹⁾	\$0.23/Option	8,871,024⁽²⁾

Notes:

⁽¹⁾ 7,510,001 represents 4.58% of the issued and outstanding Common Shares as of December 31, 2021.

⁽²⁾ 8,871,024 represents 5.42% of the issued and outstanding Common Shares as of December 31, 2021.

Stock Option Plans and Other Incentive Plans

The Stock and Incentive Compensation Plan

The Company's stock and incentive stock option plan (the "Stock Option Plan" or "Compensation Plan") was last approved by Shareholders on December 6, 2018.

The following is a summary of the material terms of the Compensation Plan:

Purpose

The purpose of the Stock Option Plan is to authorize the grant to eligible persons, being directors, employees, officers or eligible consultants and investor relations persons (collectively, the "**Eligible Participants**") of the Company to acquire common shares in the capital of the Company and thus benefit the Company by enabling it to attract, retain and motivate Eligible Participants by providing them with the opportunity, through options, to acquire an increased proprietary interest in the Company.

Eligible Participants

Options may be granted to Eligible Participants. Subject to the provisions of the Stock Option Plan, the board of the Company ("**Company Board**") has the authority to determine the terms, limitations, restrictions and conditions applicable to the vesting or to the exercise of an Option, including, without limitation, the nature and duration of the restrictions, if any, to be imposed on the sale or other disposition of Company Shares acquired on exercise of an Option.

Vesting

The Company Board will establish vesting and other terms and conditions for an Option at the time each Option is granted.

Securities Issuable under the Stock Option Plan

The aggregate number of Company Shares reserved for issuance for all Options granted under the Stock Option Plan must not exceed 10% of the Company Shares issued and outstanding (on a non-diluted basis) at the time of granting the Option.

The maximum number of Company Shares which may be reserved for issuance to insiders under the Stock Option Plan, and any other stock option plans of the Company or options for services, shall be 10% of the Company Shares issued and outstanding at the time of the grant (on a non-diluted basis).

The maximum number of Company Shares which may be issued to insiders under the Stock Option Plan, together with any other previously established or proposed share compensation arrangements, within any one-year period shall be 10% of the outstanding issue. The maximum number of Company Shares which may be issued to any one insider and his

or her associates under the Stock Option Plan, together with any other previously established or proposed share compensation arrangements, within a one-year period shall be 5% of the Company Shares outstanding at the time of the grant (on a non-diluted basis).

Exercise Price and Term

Each Option is confirmed by an option agreement or option grant letter or other form of confirmation (electronic or otherwise) as prescribed by the Company Board from time to time. The Company Board shall establish the exercise price of an Option at the time the Option is granted. The exercise price may not be less than the "market price" (as defined in the Stock Option Plan) on the date of grant, being the greater of the closing market price of the Company Shares on the CSE on: (a) the trading day prior to the date of grant of the Options; and (b) the date of grant of the Options. In the event that the Company Shares are not then listed and posted for trading on the CSE or such other stock exchange or quotation system on which the Company Shares are listed or quoted from time to time, the market price shall be determined by the Company Board in its sole discretion.

Cessation or Termination of Options

Subject to the death of an optionee, if any optionee who is a service provider shall cease to be an Eligible Participant for any reason (whether or not for cause) the optionee may, but only within the period of 90 days (unless such period is extended by the Company Board or a committee of the Company Board, as applicable, to a date no later than the date the relevant options would have otherwise expired, and approval is obtained from the stock exchange on which the Company Shares trade where required), or 30 days if the Eligible Participant is an Investor Relations Person (as such term is defined under the Stock Option Plan) unless such period is extended by the Company Board or a committee of the Company Board, as applicable, to a maximum of one year next succeeding such cessation, and approval is obtained from the stock exchange on which the Company Shares trade where required), next succeeding such cessation and in no event after the expiry date of the optionee's option, exercise the optionee's option unless such period is extended as provided below.

In the event of the death of an optionee during the currency of the optionee's option, the option granted to the optionee shall be exercisable within, but only within, the period of one year next succeeding the optionee's death (unless such period is extended by the Company Board or a committee of the Company Board, as applicable, to a date no later than the date the relevant options would have otherwise expired, and approval is obtained from the stock exchange on which the Issuer Shares trade where required).

Assignability

Options granted under the Stock Option Plan shall be non-assignable and non-transferable by an optionee otherwise than by will or by the laws of descent and distribution, and such Option shall be exercisable, during an optionee's lifetime, only by the optionee.

Amendment Provisions

The Company Board or a committee of the Company Board, as applicable, may at any time amend or terminate the Stock Option Plan, but where amended, such amendment is subject to regulatory approval. Notwithstanding the foregoing, in the event the Company Shares are listed on the CSE, the terms of an option may not be amended once issued; and if an option is cancelled prior to its expiry date, the Company must post notice of the cancellation and shall not grant new Options to the same Eligible Participant until 30 days have elapsed from the date of cancellation.

Oversight and description of director and Named Executive Officer compensation

The Board relies heavily on the recommendations of the Compensation Committee and any independent consultants that it retains from time to time to provide analyses, recommendations and benchmarks, having regard to the total compensation levels among comparable companies, to ensure that the Company is compensating its NEOs fairly and competitively, and is able to attract and retain qualified individuals to help the Company continue to meet its business-plan objectives

Compensation objectives are established by the Compensation Committee, and for 2021 include the following:

- attracting and retaining highly qualified individuals;
- creating among directors, officers, consultants and employees, a corporate environment which will align their interests with those of the shareholders; and
- ensuring competitive compensation that is also affordable for the Company.

The compensation program is designed to provide competitive levels of compensation. The Company recognizes the need to provide a total compensation package that will attract and retain qualified and experienced executives as well as align the compensation level of each executive to that executive's level of responsibility. In general, the Company's directors and Named Executive Officers may receive compensation that is comprised of the following components:

- salary, wages or contracted payments.
- extended medical, dental and insurance benefits ("**Benefits**")
- Options; and
- cash bonuses.

The objectives and reasons for this system of compensation are to allow the Company to remain competitive compared to its peers in attracting experienced personnel. The salaries are set on the basis of a review and comparison of salaries paid to executives at similar companies.

Option grants are designed to reward directors and Named Executive Officers for success on a similar basis as the Shareholders, although the level of reward provided by a particular Option grant is dependent upon the volatility of trading of the Common Shares on the CSE, as well as general volatility of the capital markets.

Specific goals and performance measurement objectives for the NEOs relating to 2021 have not been approved at the date of this Circular. It is expected that the general categories for individual performance weighting will be reflective of the business strategy implementation priorities of the Company in 2021.

Employment, consulting and management agreements

As at the date of this Information Circular, the Company does not have any written employment, consulting or management agreements in place with any NEOs. In addition, no NEO of the Company is entitled to any payment with respect to change of control, severance, termination or construction dismissal.

Oversight and description of director and named executive officer compensation

The Board has a compensation committee which manages all tasks relating to the development and assessment of the compensation paid to both the NEOs and directors. Compensation is reviewed on an annual basis. The Company's compensation program is designed to provide competitive levels of compensation, a significant portion of which is dependent upon individual and corporate performance and contribution to increasing shareholder value. The Board recognizes the need to provide a total compensation package that will attract and retain qualified and experienced executives as well as align the compensation level of each executive to that executive's level of responsibility.

The objectives and reasons for this system of compensation are generally to allow the Company to remain competitive compared to its peers in attracting and retaining experienced personnel. In general, a NEO's compensation is comprised of salary, wages or contractor payments and stock option grants.

Salary, wages or contractor payments for each NEO are based on the position held, the related responsibilities and functions performed by the NEO and salary ranges paid to executives at similar companies. Stock option grants are designed to reward the NEOs for success on a similar basis as the shareholders of the Company, but these rewards are highly dependent upon the volatile stock market, much of which is beyond the control of the NEOs. When new options are granted, the Board takes into account the previous grants of options, the number of stock options currently held, position, overall individual

performance, anticipated contribution to the Company's future success and the individual's ability to influence corporate and business performance. The purpose of granting such stock options is to assist the Company in compensating, attracting, retaining and motivating the officers, directors and employees of the Company and to closely align the personal interest of such persons to the interest of the shareholders.

The exercise price of the stock options granted is generally determined by the market price at the time of grant, less any allowable discount. At this time the Board has not established any performance criteria or goals. There were no significant changes to the Company's compensation policies during or after the most recently completed financial year that could or would have affected the Named Executive Officers' compensation.

Pension

The Company does not have a pension plan under which benefits are determined primarily by final compensation (or average final compensation) and years of service.

DIRECTOR COMPENSATION

The following table sets forth information concerning the annual and long-term compensation in respect of the directors of the Company, other than the NEOs, during the fiscal year ended December 31, 2021.

Director Compensation Table

Name	Fees earned (\$)	Share-based awards (\$) ⁽¹⁾	Option-based awards (\$)	Non-equity incentive plan compensation (\$) ⁽²⁾	Pension value (\$) ⁽³⁾	All other compensation (\$)	Total Compensation (\$)
Facundo Garretón	-	-	-	-	-	-	-
Catherine Lathwell	-	-	-	-	-	-	-
Patricio Villalba	-	-	-	-	-	-	-
Sebastian Hochbaum	-	-	-	-	-	-	-
Joaquin Barbera	-	-	-	-	-	-	-
Christian Toro ⁽⁴⁾	-	-	-	-	-	-	-
Paola Casteñeda ⁽⁴⁾	-	-	-	-	-	-	-
Francisco Sole ⁽⁴⁾	-	-	-	-	-	-	-
Fabio Valencia ⁽⁴⁾	-	-	-	-	-	-	-
Andres Vidal ⁽⁴⁾	-	-	-	-	-	-	-

(1) The Company does not have a share-based awards plan for directors

(2) The Corporation does not have a non-equity incentive plan for directors.

(3) The Corporation does not have a pension plan.

(4) Resigned effective January 20, 2021.

CORPORATE GOVERNANCE DISCLOSURE Form 58-101F2 Disclosure (Venture Issuers)

The following is a summary of the Company's corporate governance disclosure required by Form 58-101F2 of National Instrument 58-101, *Disclosure of Corporate Governance Practices*.

Board of Directors

The Board, at present, is composed of five directors, and all are considered to be "independent", as that term is defined in applicable securities legislation. In determining whether a director is independent, the Board, among other things, considers whether the director has a relationship which could be perceived to interfere with the director's ability to objectively assess the performance of management.

The Board is responsible for approving long-term strategic plans and annual operating plans and budgets recommended by management. Board consideration and approval is also required for material contracts and business transactions, and all debt and equity financing transactions.

The Board delegates to management responsibility for meeting defined corporate objectives, implementing approved strategic and operating plans, carrying on the Company's business in the ordinary course, managing the Company's cash flow, evaluating new business opportunities, recruiting staff and complying with applicable regulatory requirements. The Board also looks to management to furnish recommendations respecting corporate objectives, long-term strategic plans and annual operating plans.

See also information at Schedule "A" – Mandate of the Board of Blueberries Medical Corp.

Other Public Company Directorships

None of the directors are currently directors of any other reporting issuers.

Orientation and Continuing Education

The Company has not yet developed an official orientation or training program for new directors. As required, new directors have the opportunity to become familiar with the Company by meeting with the other directors, officers and employees. Orientation activities are tailored to the particular needs and experience of each director and the overall requirements of the Board.

Interlocking Boards and CEO Board restriction

None of the Company's directors currently serve together on the board of any other reporting issuer.

Director Term Limits

The Company has not adopted term limits for the directors of the Board as term limits could result in the loss of directors who have been able to develop, over a period of time, significant insight into the Company and its operations and an institutional memory that benefits the Board as well as the Company and its stakeholders.

Retirement Policy

The Company does not currently have a retirement policy requiring its directors to retire at a certain age.

Ethical Business Conduct

The Board monitors the ethical conduct of the Company and ensures that it complies with the applicable legal and regulatory requirements of relevant securities commissions and stock exchanges. The Company has a Code of Business Conduct and Ethics, which can be found on the Company's website at <https://blueberriesmed.com/en>

In general, the Board has found that the fiduciary duties placed on individual directors by the Company's governing corporate legislation and the common law, as well as the restrictions placed by applicable corporate legislation on the individual director's participation in decisions of the Board in which the director has an interest, have been sufficient to ensure that the Board operates independently of management and in the best interests of the Company.

Complaints Procedures

The Company has also adopted specific procedures to receive complaints and submissions relating to accounting matters (the "**Whistleblower Policy**", included as a schedule to the Code of Conduct and Business Ethics), which outline complaint procedures for financial concerns and other corporate issues. A Complaints Officer has been appointed under the Whistleblower Policy to whom complaints and submissions can be made regarding accounting, internal accounting controls or auditing matters or issues of concern regarding accounting or auditing matters.

Excluding complaints or submissions made directly to the Complaints Officer regarding financial, accounting or auditing matters, the Board does not formally monitor compliance with the Codes. Management is responsible to report to the CGNC when they become aware of any breaches or alleged breaches of the Codes and complaints made by suppliers or employees against the Company or any director, employee or officer. In the event of a violation of any of the Code of Conduct and Business Ethics, the applicable committee of the Board will investigate the breach or alleged breach and, if appropriate, recommend corrective disciplinary action, including, if warranted, termination of employment. In the event that a breach or alleged breach relates to financial, accounting or auditing issues, the Complaints Officer and the Audit Committee will share responsibility to investigate the matter.

At the date of this Circular, there has been no conduct by a director or executive officer that constitutes a departure from the Codes and the Complaints Officer has received no complaints under the Whistleblower Policy.

Meetings and meeting attendance

All Nominees, except Joaquin Barbera, attended 100% of the Board meeting held on February 3, 2021.

Meetings without management present

During 2021, the independent members of the Board did not meet in camera at the board meeting.

Nomination of Directors

The Board does not have a formal process for identifying new candidates for Board nomination. When required, the Board collaborates with management to identify potential candidates to consider their suitability for membership on the Board.

Written Position Description of the CEO

The Board has developed a written position description for the CEO, which delineates the role and responsibilities of the CEO, along with such other responsibilities as may be delegated to the CEO by the Board or its Committees from time to time.

CEO Succession Planning

There is currently no formal process in place to manage succession planning for the position of CEO. The CGNC and the Board does not believe at this time that the Company is dependent upon any one of the individual Executives, including the CEO so as to require a formal succession plan. It is envisaged that a member of the Executive or the Board would temporarily assume the position and duties of CEO on an interim basis should the need arise while a search for a suitable candidate was undertaken. The CGNC expect to continue its ongoing review for a need to formalize a succession process in 2019 in order to ensure that a qualified successor to the Company's Chief Executive Officer position can be identified, if and when appropriate.

Corporate Governance and Nominating Committee

The Board has established a Corporate Governance and Nominating Committee that is comprised entirely of independent directors; this committee is charged with the responsibility of identifying new candidates for Board nomination, among other things. The current members of the CGNC are Mr. Patricio Villalba (chair), Catherine Lathwell and Facundo Garretón. While a formal process has not yet been developed, it is expected that Board candidates will be identified through industry contacts and search firms.

The responsibilities and powers of the Corporate Governance and Nominating Committee are set out in its written charter, and include, among other things:

- (a) monitor compliance with the Company's corporate governance policies;
- (b) develop a code or codes of business conduct and ethics for the Company and review the code(s) of business conduct and ethics and approve changes, if necessary, on an annual basis;
- (c) assist the Board in monitoring compliance with the Company's code(s) of business conduct and ethics;
- (d) propose agenda items and content for submissions to the Board related to corporate governance issues and provide periodic updates on recent developments in corporate governance;
- (e) conduct a periodic review of the relationship between management and the Board and its effectiveness;
- (f) review on an ongoing basis the Company's approach to governance, and recommend the establishment of appropriate governance policies and standards in light of securities law and exchange requirements;
- (g) review and recommend to the Board changes to the way directors are to be elected to the Board by Shareholders, if appropriate;
- (h) conduct at least annually an evaluation of the effectiveness of the Board and its Committees and recommend any changes to the composition of the Board;
- (i) conduct an annual evaluation of the overall performance and effectiveness of individual directors;

- (j) recommend to the Board a slate of candidates for presentation to the Shareholders at each annual meeting of Shareholders and one or more nominees for each vacancy on the Board that occurs between annual meetings of Shareholders, if any;
- (k) recommend to the Board qualified members of the Board for membership on Committees of the Board and recommend a qualified member of the Board to act as Chair of the Board;
- (l) provide orientation for new directors and ongoing education for all directors; and
- (m) review executive officer succession plans and ensure that a qualified successor to the Company's Chief Executive Officer position is identified, if and when appropriate.

Compensation

The Board has also established a Compensation Committee, which is comprised entirely of independent directors. The current members of the Compensation Committee are Messrs. Patricio Villalba (chair), Catherine Lathwell and Facundo Garretón. Each of the Committee members has served for several years in either a senior management capacity, or as a director and compensation committee member of an issuer, at which they would have had direct responsibility for reviewing performance of direct reports, hiring, setting of performance goals and objectives and setting salaries.

The Compensation Committee has adopted a written charter, pursuant to which its responsibilities include, among other things:

- (a) annually review and approve corporate goals and objectives relevant to the CEO and executive officer compensation, evaluate the performance of the CEO and each executive officer's performance in light of those goals and objectives, and recommend to the Board for approval the compensation level for the CEO and each executive officer based on this evaluation;
- (b) administer and make recommendations to the Board regarding the adoption, amendment or termination of the Company's incentive compensation plans and equity-based plans (including specific provisions) in which the CEO and executive officers may participate;
- (c) recommend to the Board compensation and expense reimbursement policies for Board members; and
- (d) review and approve employment agreements, severance arrangements and change in control agreements and other similar arrangements for the CEO and executive officers.

The Company has not completed an assessment of potential risks associated with Blueberries' compensation policies and practices. The Compensation Committee is responsible for annually reviewing Blueberries' compensation arrangements, as set out above, and may determine to undertake such an assessment during a later period.

Audit Committee

The Company has an Audit Committee, which is currently comprised of Catherine Lathwell (chair), Patricio Villalba and Facundo Garretón, each of whom is considered independent and financially literate in accordance with applicable securities laws. The Audit Committee has adopted a written charter that sets out its duties and responsibilities. For more information see section entitled "*Audit Committee Information*" below.

Other Board Committees

Other than as described herein, the Board has not appointed any other committees to date.

Assessments

The Board has not, as yet, adopted formal procedures for assessing the effectiveness of the Board, its committees or individual directors, and such matters are considered on a case-by-case basis.

AUDIT COMMITTEE INFORMATION

Pursuant to the provisions of the *Business Corporations Act* (British Columbia) and National Instrument 52-110 – *Audit Committees ("NI 52-110")*, the Company is required to have an Audit Committee and to disclose certain information concerning the constitution of its audit committee and its relationship with the Company's independent auditor.

The general function of the Audit Committee is to review the overall audit plan and the Company's system of internal controls, to review the results of the external audit, and to resolve any potential dispute with the Company's auditor.

Audit Committee Charter

A copy of the charter of the Audit Committee is attached to this Circular as Schedule "B".

Composition of the Audit Committee

The Company's Audit Committee consists of Catherine Lathwell (chair) Patricio Villalba and Facundo Garretón

NI 52-110 provides that a member of an audit committee is "independent" if the member has no direct or indirect "material relationship" with the Company, which, for the purposes of NI 52-110 means a relationship which could, in the view of the Board, be reasonably expected to interfere with the exercise of the member's independent judgment. All of the Company's current Audit Committee members are "independent" within the meaning of NI 52-110.

NI 52-110 provides that an individual is "financially literate" if he or she has the ability to read and understand a set of financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Company's financial statements. All of the members of the Audit Committee are "financially literate" as that term is defined. The following sets out the Audit Committee members' education and experience that is relevant to the performance of his responsibilities as an audit committee member.

Relevant Education and Experience

All members of the Audit Committee have:

- (a) an understanding of the accounting principles used the Company to prepare its financial statements;
- (b) the ability to assess the general application of such principles in connection with accounting for estimates, accruals and provisions;
- (c) experience preparing, auditing, analyzing or evaluating financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably be expected to be raised by the Company's financial statements, or experience actively supervising one or more individuals engaged in such activities; and
- (d) an understanding of internal controls and procedures for financial reporting.

Facundo Garretón

Mr. Garretón is a successful entrepreneur in the fields of innovation, technology and life sciences, and a former member of Congress in Argentina. His successful track record as an entrepreneur includes founding InvertirOnline.com, one of Latin America's largest online brokerage firms, as well as founding and serving as director of SocialLab and Sistema B, the most important platform for social entrepreneurs in Latin America. Mr. Garretón also has strategic involvement with other cannabis companies including YVY Life Sciences in Uruguay and Flow Kana in California. Mr. Garretón is a director of various successful companies such as: YVY Life Sciences, Pachama.com, VU Security, Untech.bio, Bulltick, GoodPeople, Inipop.com and others. Also, he is an investor in companies such as ClaraFoods, TheNotCompany, Blue Planet Ecosystems, Memphis Meat, Cambridge Crops, Electro-Active Technologies (EAT), Unbox Robotics, Prellisbio.com and MycoWorks.

Ms. Lathwell CPA, CGA, is a graduate of the University of Toronto with distinction and a Chartered Professional Accountant. She is the VP of Finance and Administration at JUMP Math, a Canadian Registered Charity in the area of childhood math education and the Chief Financial Officer of White Gold Corp. (TSXV: WGO). Ms. Lathwell has developed financial literacy through her many years as a full cycle accountant for private and public companies and her studies in the area.

Mr. Villalba has over 20 years of experience in Latin America in the mining, exploration, logistics and trading of hydrocarbons, notably in Colombia and Mexico, and he has developed an extensive network in governmental and private organizations at both the local and international levels. Mr. Villalba has an active presence in up-mid and downstream projects with important achievements in the development of integral logistics, achieving economic efficiencies, delivery times and commercialization, specifically in Mexico.

Reliance on Certain Exemptions

At no time since the commencement of the Company's most recently completed financial year has the Company relied on the exemptions in Section 2.4 of NI 52-110 (De Minimis Non-Audit Services); Section 3.2 (Initial Public Offerings); Section 3.4 (Events Outside Control of Member); Section 3.5 (Death, Disability or Resignation of Audit Committee Member); an exemption from NI 52-110, in whole or in part, granted under Part 8 (Exemptions) of NI 52-110; the exemptions in Subsection 3.3(2) (Controlled Companies); Section 3.6 (Temporary Exemption for Limited and Exceptional Circumstances); or Section 3.8 (Acquisition of Financial Literacy).

Audit Committee Oversight

At no time since the commencement of the Company's most recently completed financial year was a recommendation of the Audit Committee to nominate and/or compensate an external auditor not adopted by the Board.

Pre-Approval Policies and Procedures

Pursuant to the terms of the Audit Committee Charter, the Audit Committee will pre-approve all non-audit services to be provided to the Company by the external auditor.

External Auditor Service Fees

The aggregate fees billed to the Company for the last two (2) financial years noted below by the Company's external auditor, MNP LLP, are as follows:

Financial Year Ending Dec. 31	Audit Fees ⁽¹⁾	Audit Related Fees ⁽²⁾	Tax Fees ⁽³⁾	All Other Fees ⁽⁴⁾
2021	\$110,000	\$Nil	\$17,700	\$Nil
2020	\$62,500	\$Nil	\$12,350	\$Nil

Notes:

- (1) "Audit fees" include aggregate fees billed by the Company's external auditor in each of the last two financial years noted above for audit fees.
- (2) "Audit related fees" include the aggregate fees billed in each of the last two financial years noted above for assurance and related services by the Company's external auditor that are reasonably related to the performance of the audit or review of the Company's financial statements and are not reported under "Audit fees" above. The services provided include employee benefit audits, due diligence assistance, accounting consultations on proposed transactions, internal control reviews and audit or attest services not required by legislation or regulation.
- (3) "Tax fees" include the aggregate fees billed in each of the last two financial years noted above for professional services rendered by the Company's external auditor for tax compliance, tax advice and tax planning. The services provided include tax planning and tax advice includes assistance with tax audits and appeals, tax advice related to mergers and acquisitions, and requests for rulings or technical advice from tax authorities.
- (4) "All other fees" include the aggregate fees billed in each of the last two financial years noted above for products and services provided by the Company's external auditor, other than "Audit fees", "Audit related fees" and "Tax fees" above.

Additional Information

Additional information relating to the Company is on SEDAR at www.sedar.com. Shareholders may contact the Company to request copies of the Company's financial statements and MD&A.

Financial information is provided in the Company's comparative audited annual financial statements and MD&A for its most recently completed financial year which are filed on SEDAR.

INDEBTEDNESS OF DIRECTORS AND EXECUTIVE OFFICERS

No directors, proposed nominees for election as directors, executive officers or their respective associates or affiliates, or other management of the Company, were indebted to the Company as of the end of the Company's most recently completed financial year or as at the date hereof.

INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS

An informed person is one who, generally speaking, is a director or executive officer or a 10% shareholder of the Company.

To the knowledge of management of the Company, no informed person or nominee for election as a director of the Company or any associate or affiliate of any informed person or proposed director had any interest in any transaction which has materially affected or would materially affect the Company or any of its subsidiaries during the Company's most recently completed financial year ended December 31, 2021, or has any interest in any material transaction in the current year other than as set out herein.

MANAGEMENT CONTRACTS

Except as otherwise disclosed herein, there are no management functions respecting the Company, which are to any substantial degree performed by a person other than the directors or senior officers of the Company or a subsidiary thereof.

ADDITIONAL INFORMATION

Additional information relating to the Company is available through the internet on the Company's issuer profile on SEDAR which can be accessed at www.sedar.com. Financial information on the Company is provided in the comparative financial statements and management discussion and analysis of the Company which can also be accessed at www.sedar.com. Shareholders may request copies of the Company's financial statements and MD&A by contacting the Company at 82 Richmond Street East, Toronto, Ontario, Canada M5C 1P1.

ADDITIONAL BUSINESS

The Company will consider and transact such other business as may properly come before the Meeting or any adjournment thereof. Management of the Company knows of no other matters to come before the Meeting other than those referred to in the Notice of Meeting. Should any other matters properly come before the Meeting the Common Shares represented by the proxy solicited hereby will be voted on such matter in accordance with the best judgment of the persons voting by proxy.

Matters which may properly come before the Meeting are any matters not effecting a change in the Articles or Memorandum of the Company, or not disposing of all or substantially all of the assets or undertaking of the Company.

APPROVAL OF INFORMATION CIRCULAR

The undersigned hereby certifies that the Board of Directors of the Company has approved this Information Circular.

DATED at Toronto, Ontario, this 25th day of August 2022.

Blueberries Medical Corp.

"Facundo Garretón"
Chief Executive Officer

SCHEDULE "A" – MANDATE OF THE BOARD OF BLUEBERRIES MEDICAL CORP.

General

1. The directors are elected by the shareholders and are responsible for the stewardship of the business and affairs of Blueberries Medical Corp. ("**Blueberries**", or the "**Corporation**"). The Board of Directors (the "**Board**") seeks to discharge this responsibility by reviewing, discussing and approving the Company's strategic planning and organizational structure and supervising management to oversee that the strategic planning and organizational structure enhance and preserve the business of the Company and the underlying value of the Company.

Composition

2. The Board believes that better corporate governance is promoted when a board of directors is made up of highly qualified individuals i) from diverse backgrounds who reflect the changing population demographics of the markets in which the Company operates, ii) of each gender, and iii) reflective of the talent available with the required expertise. When considering recommendations for nomination to the Board, the Board shall consider:
 - (a) diversity criteria including gender, age, ethnicity and geographic background; and
 - (b) candidates who are highly qualified based on their experience, functional expertise, and personal skills and qualities.

Notwithstanding this, the Company does not support the adoption of quotas to support its belief in the importance of diversity. In addition to the criteria set out above and elsewhere herein, employees and directors of the Company ("**Directors**") will be recruited and promoted based upon their ability and contributions.

3. The Directors shall consist of persons who possess skills and competencies in areas that are:
 - (a) necessary to enable the Board and Board committees to properly discharge their duties and responsibilities; and
 - (b) relevant to the Company's activities.
4. At least a majority of the directors shall be individuals who are "independent" directors in accordance with applicable securities laws and stock exchange policies. Subject to the size and operations of the Company, the Board is committed to setting measurable objectives for the long-term goal of improving gender representation across all levels of the organisation. Annually, the Board will report to the Company's shareholders the following:
 - (a) a summary of the Company's progress towards achieving the measurable objectives set under this Policy; and
 - (b) details of the measurable objectives set under this Policy for the subsequent financial year.
5. The Board does not believe it should establish term limits for directors as term limits could result in the loss of Directors who have been able to develop, over a period of time, significant insight into the Company and its operations and an institutional memory that benefits the Board as well as the Company and its stakeholders. The Board, on its initiative and on an exceptional basis, may exercise discretion to introduce maximum terms or mandatory retirement where it considers that such a limitation would benefit the Company and its stakeholders.
6. Subject to the limitations herein, the Corporate Governance and Nominating ("**CG&N**") Committee of the Board will annually (and more frequently, if appropriate) recommend candidates to the Board for election or appointment as Directors, taking into account the Board's conclusions with respect to the appropriate size and composition of the Board and Board committees, the competencies and skills required to enable the Board and Board Committees to properly discharge their responsibilities, and the competencies and skills of the current Board.

7. No director should serve on the board of a regulatory body with oversight of the Company. Each director should, when considering membership on another board or committee, make every effort to ensure that such membership will not impair the Director's time and availability for his or her commitment to Blueberries as well as his or her ability to exercise their fiduciary duties as directors.
Directors should advise the chair of the CG&N Committee and the Chief Executive Officer ("**CEO**") of the Company before accepting membership on other public company boards of directors, or any audit committee, or other significant committee assignment on any other board of directors, or establishing other significant relationships with businesses, institutions, governmental units or regulatory entities, particularly those that may result in significant time commitments or a change in the director's relationship to the Company.
No director shall serve on more than four public company boards in aggregate.
8. Without prior approval of the CG&N Committee, the CEO of the Company should not serve on the board of any other public company; and at no time shall the CEO serve on more than one other public company.
9. The Board approves the final choice of candidates.
10. The shareholders of the Company elect the Directors annually.
11. A Lead Director is elected annually at the first meeting of the Board following the shareholders' meeting. This role is normally filled by the Chair. At any time when the Chair is an employee of the Company, the non-management directors shall select an independent director to carry out the functions of a Lead Director. This person would chair regular meetings of the non-management directors and assume other responsibilities which the non-management directors as a whole have designated.
12. The Secretary of the Company (the "**Secretary**") shall be secretary of the Board.
13. Directors are expected to comply with the Corporation's Code of Business Conduct and Ethics and its Directors' Code of Ethics.

Meetings, Proceedings and Administration

14. The quorum for the transaction of business at any meeting of the Board shall be a majority of directors or such other number of directors as the Board may from time to time determine according to the articles of incorporation of the Company.
15. The Board shall have at least four scheduled meetings per year. The Chair of the Board ("**Chair**") and the CEO shall develop the agenda for each meeting.
16. Committee meetings may be held in person, by video-conference, by telephone or by any combination of the foregoing.
17. Independent directors shall meet at the end of each Board meeting without management and non-independent directors.
18. At meetings of the Board, resolutions shall be approved by a majority of the votes cast on the resolution.
19. Regularly scheduled Board meetings shall normally proceed as follows:
 - (a) Review and approval of the minutes of the preceding Board meeting;
 - (b) Business arising from the previous minutes;
 - (c) Reports of committees;
 - (d) Report of the President and CEO, financial and operational reports;
 - (e) Other business;
 - (f) In-camera session with solely independent directors; and
 - (g) Adjournment.

20. A secretary should be named for each Board and committee meeting and minutes should be circulated in due course after such meeting. This role is normally filled by the Secretary.
21. Minutes of the committee meetings will be made available to each Board member upon request.

Authority and Responsibilities

22. The powers of the Board may be exercised at a meeting for which notice has been given and at which a quorum is present or, in appropriate circumstances, by resolution in writing signed by all the directors.
23. The Board is authorized to retain, and to set and pay the compensation of, independent legal counsel and other advisers if it considers this appropriate.
24. The Board is authorized to invite officers and employees of the Company and outsiders with relevant experience and expertise to attend or participate in its meetings and proceedings, if it considers this appropriate.
25. The Board and the Directors have unrestricted access to the advice and services of the Secretary and outside auditors and legal counsel.
26. The Board discharges its responsibility for overseeing the management of the Company's business by delegating to the Company's senior officers the responsibility for day-to-day management of the Company. The Board discharges its responsibilities directly and through its committees; namely, the Audit Committee, the Compensation Committee the CG&N Committee, and the Health, Safety and Sustainability Committee. In addition to these regular committees, the Board may appoint ad hoc committees periodically to address issues of a more short-term nature. The Board's primary roles are overseeing corporate performance and providing quality, depth and continuity of management to meet the Company's strategic objectives.
27. The Board is authorized through the CG&N Committee to conduct evaluations of the Board and the Directors and perform succession planning activities
28. Responsibilities of the Board include, but are not limited to:
 - (a) selecting and appointing, evaluating and (if necessary) terminating the CEO;
 - (b) satisfying itself as to the integrity of the CEO and other executive officers and ensuring that they promote a culture of integrity throughout the organization;
 - (c) adopting a strategic planning process, approving strategic plans, and monitoring performance against plans;
 - (d) reviewing the Company's long-term strategy annually;
 - (e) reviewing and approving annual operational budgets, capital expenditure limits and corporate objectives, and monitoring performance on each of the above;
 - (f) approving all decisions involving unbudgeted expenditures individually in excess of \$100,000, or in aggregate in excess of \$250,000;
 - (g) reviewing policies and procedures to identify business risks, and ensure that systems and actions are in place to monitor them;
 - (h) reviewing policies and processes to ensure that the Company's internal control and management information systems are operating properly;
 - (i) approving the audited annual financial statements, MD&A, annual information form, information circular, and other filings required under applicable securities laws;
 - (j) assessing the contribution of the Board, committees and all directors annually, and planning for succession of the Board;

- (k) reviewing and approving committee chair nominees from time to time as recommended by the respective committees;
- (l) assessing the effectiveness of the Board and each of the directors annually at a meeting of the Board to determine if any changes to the Board size or make-up are required;
- (m) assessing the effectiveness of each director by way of a formal review undertaken by with the Chair of the Board, Lead Director or Chair of the CG&N Committee where each director will receive peer feedback from other directors to determine how they could operate more effectively within the Board;
- (n) arranging formal orientation programs for new directors, where appropriate;
- (o) considering diversity in the selection criteria of new Board members;
- (p) establishing and maintaining an appropriate system of corporate governance including practices to ensure the Board functions effectively and independently of management, including reserving a portion of all Board and its committee meetings for in camera discussions without management present;
- (q) approving and monitoring compliance with significant policies and procedures by which the Company is operated;
- (r) proactively monitoring the Company's performance in meeting standards and objectives related to those diversity initiatives established by the Board, and progress in achieving them;
- (s) ensuring that a comprehensive compensation strategy is maintained which includes competitive industry positioning, weighting of compensation elements and relationship of compensation to performance;
- (t) ensuring that an adequate system of internal control is maintained to safeguard the Company's assets and the integrity of its financial and other reporting systems;
- (u) ensuring that the Company has in place a communication and disclosure policy which supports the oversight of public communication and disclosure and enables disclosure controls in compliance with all legal and regulatory requirements and that such is reviewed at such intervals as the Board deems appropriate. Directors must adhere to the Company's disclosure policy;
- (v) providing oversight of environmental matters;
- (w) reviewing and considering for approval all amendments or departures proposed by management from established strategy, capital and operating budgets, or matters of policy, which diverge from the ordinary course of business;
- (x) ensuring that a process is established that adequately provides for management succession planning, including the appointing, training, and monitoring of senior management;
- (y) annually assessing the charters of Board committees and revising where necessary;
- (z) adhering to all other Board responsibilities set out in the Company's by-laws and other statutory and regulatory requirements; and
- (aa) enhancing the reputation, goodwill and image of the Company.

29. Responsibilities of the Chair of the Board include but are not limited to:

- (a) providing leadership to the Board with respect to its functions as described in this Mandate and as otherwise may be appropriate, including overseeing the logistics of the operations of the Board;
- (b) chairing meetings of the Board, unless not present including in camera sessions;
- (c) ensuring that the Board meets on a regular basis and at least quarterly;
- (d) establishing a calendar for holding meetings of the Board;

- (e) establishing the agenda for each meeting of the Board, with input from other Board members and any other parties as applicable;
 - (f) ensuring that Board materials are available to any director on request;
 - (g) ensuring that the members of the Board understand and discharge their duties and obligations;
 - (h) fostering ethical and responsible decision making by the Board and its individual members;
 - (i) overseeing the structure, composition, membership and activities of the Board;
 - (j) ensuring that resources and expertise are available to the Board so that it may conduct its work effectively and efficiently;
 - (k) pre-approving work to be undertaken for the Board by consultants;
 - (l) facilitating effective communication between members of the Board and management;
 - (m) attending each meeting of shareholders to respond to any questions from shareholders as may be put to the Chair;
 - (n) communicate with directors between meetings;
 - (o) attend key functions of the Company;
 - (p) meet with major shareholder groups; and
 - (q) act as Chair at any annual and, if applicable, special meeting of shareholders of the Company.
30. Expectations of Directors include but are not limited to:
- (a) maintaining a high attendance record at meetings of the Board and the committees of which they are members. Directors are encouraged to attend at least 75% of meetings of the Board in the absence of extenuating circumstances. Attendance by telephone or video conference may be used to facilitate a director's attendance;
 - (b) reviewing the materials circulated in advance of meetings of the Board and its committees and being prepared to discuss the issues presented. Directors are encouraged to contact the Chair of the Board, the CEO and any other appropriate executive officer(s) to ask questions and discuss agenda items prior to meetings;
 - (c) being sufficiently knowledgeable of the business of Blueberries, including its financial statements, and the risks it faces, ensuring active and effective participation in the deliberations of the Board and of each committee on which he or she serves.
 - (d) freely to contact the CEO at any time to discuss any aspect of the Company's business. Directors should use their judgement to ensure that any such contact is not disruptive to the operations of the Company. The Board expects that there will be frequent opportunities for Directors to meet with the CEO in meetings of the Board and committees, or in other formal or informal settings.
 - (e) Maintaining the confidentiality of the proceedings and deliberations of the Board and its committees. Each Director will maintain the confidentiality of information received in connection with his or her service as a director.
31. Expectations of Management of Blueberries
- (a) at the request of the Board, report on the Company's performance, management's concerns and any other matter the Board or its Chair may deem appropriate. Management must promptly report to the Chair any significant developments, changes, transactions or proposals respecting Blueberries.
 - (b) prepare and present to the Board annually (or more frequently if appropriate) a business plan and budget, and report regularly to the Board on the Company's performance against the business plan and budget;

- (c) review and update annually (or more frequently if appropriate) the Company's strategic plan, and report regularly to the Board on the implementation of the strategic plan in light of evolving conditions;
- (d) report regularly to the Board on the Company's business and affairs and on any matters of material consequence for the Company and its shareholders;
- (e) speak for the Company in its communications with shareholders and the public in accordance with the Company's Disclosure Policy;
- (f) comply with any additional expectations that are developed and communicated during the annual strategic planning and budgeting process and during regular Board and committee meetings;
- (g) implement policies and practices to achieving diversity initiatives determined by the Board and report to the Board on the progress toward and achievement of such diversity initiatives;
- (h) promote a work environment that values and utilizes the contributions of employees with a variety of backgrounds, experiences and perspectives through awareness of the benefits of workforce diversity and successful management of diversity; and
- (i) consult the Board with respect to all matters which by law require Board approval

This Mandate was approved and adopted by the Board on May 21, 2020.

SCHEDULE "B" - THE AUDIT COMMITTEE CHARTER

FORM 52 – 110F2

1. ROLE AND OBJECTIVE

The Audit Committee (the "**Committee**") is appointed by and reports to the board of directors (the "**Board**") of Blueberries Medical Corp. (the "**Corporation**"). The Committee assists the Board in fulfilling its oversight responsibilities relating to financial accounting and reporting process and internal controls for the Corporation.

The Committee and its membership shall to the best of its ability, knowledge and acting reasonably, meet all applicable legal, regulatory and listing requirements, including, without limitation, those of any stock exchange on which the Corporation's shares are listed, the *Business Corporations Act* (British Columbia) (the "**BCBCA**"), and all applicable securities regulatory authorities.

2. COMPOSITION

- The Committee shall be composed of three or more directors as shall be designated by the Board from time to time.
- A majority of members of the Committee shall be "independent"; and all shall be financially literate (as such terms are defined under applicable securities laws and exchange requirements for audit committee purposes).
- Each member of the Committee shall be able to read and understand fundamental financial statements, including a company's balance sheet, income statement and cash flow statement.
- At least one member of the Committee shall have sufficient experience to be considered a Financial Expert, where such is determined by having been a chief financial officer, chartered or certified public accountant, certified management accountant, or partner of an accounting firm.
- Members of the Committee shall be appointed at a meeting of the Board, typically held immediately after the annual shareholders' meeting. Each member shall serve until his/her successor is appointed unless he/she shall resign or be removed by the Board or he/she shall otherwise cease to be a director of the Corporation. Any member may be removed or replaced at any time by the Board.
- Where a vacancy occurs at any time in the membership of the Committee, it may be filled by a vote of a majority of the Board.
- A Chair of the Committee shall be designated by the Board or, if it does not do so, the members of the Committee shall elect a chair by vote of a majority of the full Committee membership. The Chair of the Committee shall be an independent director (as described above), and as detailed herein is charged with the responsibility of oversight over matters detailed in this Charter.
- If the Chair of the Committee is not present at any meeting of the Committee, one of the other members of the Committee present at the meeting shall be chosen by the Committee to preside.
- The Chair of the Committee presiding at any meeting shall not have a casting vote.
- The Committee shall appoint a secretary (the "**Secretary**") who need not be a member of the Committee or a director of the Corporation. The Secretary shall keep minutes of the meetings of the Committee. This role is normally filled by the Secretary of the Corporation.
- No Committee member shall simultaneously serve on the audit committee of more than two other public companies with active business operations or significant assets.

3. MEETINGS

- The Committee shall meet at least quarterly, at the discretion of the Chair or a majority of its members, as circumstances dictate or as may be required by applicable legal or listing requirements, provided that meetings of the Committee shall be convened whenever requested by the external auditors (the "**Independent Auditors**") or any member of the Committee in accordance with the BCBCA.
- The Chair of the Committee, or his or her designee, shall prepare and/or approve an agenda in advance of each meeting.
- Notice of the time and place of every meeting may be given orally, in writing, by facsimile or by e-mail to each member of the Committee at least 48 hours prior to the time fixed for such meeting.
- A member may in any manner waive notice of the meeting. Attendance of a member at the meeting shall constitute waiver of notice of the meeting, except where a member attends a meeting for the express purpose of objecting to the transaction of any business on the grounds that the meeting was not lawfully called.
- Any member of the Committee may participate in the meeting of the Committee by means of conference telephone or other communication equipment, and the member participating in a meeting pursuant to this paragraph shall be deemed, for purposes hereof, to be present in person at the meeting.
- A majority of Committee members, present in person, by video-conference, by telephone or by a combination thereof, shall constitute a quorum.
- If within one hour of the time appointed for a meeting of the Committee, a quorum is not present, the meeting shall stand adjourned to the same hour on the second business day following the date of such meeting at the same place. If at the adjourned meeting a quorum as hereinbefore specified is not present within one hour of the time appointed for such adjourned meeting, such meeting shall stand adjourned to the same hour on the second business day following the date of such meeting at the same place. If at the second adjourned meeting a quorum as hereinbefore specified is not present, the quorum for the adjourned meeting shall consist of the members then present.
- If and whenever a vacancy shall exist, the remaining members of the Committee may exercise all of its powers and responsibilities so long as a quorum remains in office for no more than six months, at which time the vacancy will be filled by a vote of a majority of the Board.
- At all meetings of the Committee, every question shall be decided by a majority of the votes cast. In case of an equality of votes, the matter will be referred to the Board for decision. Any decision or determination of the Committee reduced to writing and signed by all of the members of the Committee shall be fully effective as if it had been made at a meeting duly called and held.
- The Chief Executive Officer (the "**CEO**") and the Chief Financial Officer (the "**CFO**") of the Corporation are expected to be available to attend meetings, but a portion of every meeting will be reserved for in camera discussion without the CEO or CFO, or any other member of management, being present.
- The Committee may by specific invitation have other resource persons in attendance such officers, directors and employees of the Corporation and its subsidiaries, and other persons, including the Independent Auditors, as it may see fit, from time to time, to attend at meetings of the Committee.
- The Board may at any time amend or rescind any of the provisions hereof, or cancel them entirely, with or without substitution.
- The Committee shall have the right to determine who shall and who shall not be present at any time during a meeting of the Committee.
- Minutes of Committee meetings shall be sent to all Committee members.
- The Chair of the Committee shall report periodically the Committee's findings and recommendations to the Board.

4. RESOURCES AND AUTHORITY

- The Committee shall have access to such officers and employees of the Corporation and its subsidiaries and to such information with respect to the Corporation and its subsidiaries as it considers being necessary or advisable in order to perform its duties and responsibilities.
- The Committee shall have the authority to obtain advice and assistance from internal or external legal, accounting or other advisors and resources, as it deems advisable, at the expense of the Corporation.
- The Committee shall have the authority to communicate directly with the internal and external auditors.

5. RESPONSIBILITIES

A. Chair

To carry out its oversight responsibilities, the Chair of the Committee shall undertake the following:

- provide leadership to the Committee with respect to its functions as described in this Charter and as otherwise may be appropriate, including overseeing the logistics of the operations of the Committee;
- chair meetings of the Committee, unless not present (including in camera sessions), and reports to the Board following each meeting of the Committee on the findings, activities and any recommendations of the Committee;
- ensures that the Committee meets on a regular basis and at least four times per year;
- in consultation with the Committee members, establishes a calendar for holding meetings of the Committee;
- establish the agenda for each meeting of the Committee, with input from other Committee members, and any other parties, as applicable;
- ensures that Committee materials are available to any director on request;
- acts as liaison and maintains communication with the Chair of the Board (or Lead Director if an individual other than the Chair) and the Board to optimize and coordinate input from Board members, and to optimize the effectiveness of the Committee. This includes, at least annually and at such other times and in such manner as the Committee considers advisable, reporting to the full Board on:
 - all proceedings and deliberations of the Committee;
 - the role of the Committee and the effectiveness of the Committee in contributing to the objectives and responsibilities of the Board as a whole; and
 - principal operating and business risks identified by management and how each are either mitigated or managed.
- ensure that the members of the Committee understand and discharge their duties and obligations;
- foster ethical and responsible decision making by the Committee and its individual members;
- encourage Committee members to ask questions and express viewpoints during meetings;
- together with the Corporate Governance and Nominating Committee (the "**CG&N Committee**"), oversee the structure, composition, membership and activities delegated to the Committee from time to time;
- ensure that resources and expertise are available to the Committee so that it may conduct its work effectively and efficiently and pre-approve work to be done for the Committee by consultants;

- facilitate effective communication between members of the Committee and management;
- encourage the Committee to meet in separate, regularly scheduled, non-management, closed sessions with the Independent Auditors;
- attend each meeting of shareholders to respond to any questions from shareholders as may be put to the Chair; and
- perform such other duties and responsibilities as may be delegated to the Chair by the Board from time to time.

B. The Committee

The Committee has the authority to conduct any investigation appropriate to its responsibilities, and it may request the Independent Auditors as well as any officer of the Corporation, or legal counsel for the Corporation, to attend a meeting of the Committee or to meet with any members of, or advisors to, the Committee. The Committee shall have unrestricted access to the books and records of the Corporation and has the authority to retain, at the expense of the Corporation, special legal, accounting, or other consultants or experts to assist in the performance of the Committee's duties.

The Committee is hereby delegated the duties and powers specified in the BCBCA and, without limiting these duties and powers, the Committee will carry out the following responsibilities:

Financial Accounting and Reporting Process and Internal Controls

- review the annual audited financial statements and annual management's discussion and analysis relating to the annual audited financial statements to satisfy itself that they are presented in accordance with either International Financial Reporting Standards ("IFRS") or Canadian Generally Accepted Accounting Principles (collectively, "**applicable Accounting Principles**"), and report thereon to the Board and recommend to the Board whether or not same should be approved prior to their being filed with the appropriate regulatory authorities. The Committee shall also review and approve the interim financial statements, management's discussion and analysis relating to annual and interim financial statements, annual and interim earnings press releases and any other public disclosure documents that are required to be reviewed by the Committee under any applicable laws before the Corporation publicly discloses this information and/or prior to their being filed with the appropriate regulatory authorities. The Committee shall discuss significant issues regarding applicable Accounting Principles, practices, and judgments of management with management and the Independent Auditors as and when the Committee deems it appropriate to do so. The Committee shall satisfy itself that the information contained in the annual audited financial statements, the interim financial statements and management's discussion and analysis relating to such annual and interim financial statements is not significantly erroneous, misleading or incomplete and that the audit and review functions have been effectively carried out.
- review management's internal control report. In consultation with the Independent Auditors the Committee shall assess the integrity of management's risk assessments and internal controls over financial reporting and disclosure controls and procedures and ensure implementation of such controls and procedures.
- be satisfied that adequate procedures are in place for the review of the Corporation's public disclosure of financial information extracted or derived from the Corporation's financial statements, and periodically assess the adequacy of these procedures.
- meet no less frequently than annually with the Independent Auditors and the Chief Financial Officer or, in the absence of a Chief Financial Officer, with the officer of the Corporation in charge of financial matters, to review accounting practices, internal controls and such other matters as the Committee, Chief Financial Officer or, in the absence of a Chief Financial Officer, with the officer of the Corporation in charge of financial matters, deems appropriate.

- inquire of management and the Independent Auditors about significant risks or exposures, both internal and external, to which the Corporation may be subject, and assess the steps management has taken to minimize such risks.
- review the post-audit or management letter containing the recommendations of the Independent Auditors and management's response and subsequent follow-up to any identified weaknesses.
- oversee the Corporation's plans to adopt changes to policy choices under applicable Accounting Principles, and related disclosure obligations.
- in consultation with the CG&N Committee, ensure that there is an appropriate standard of corporate conduct including, if necessary, adopting and overseeing a corporate code of ethics for senior financial personnel.
- establish procedures for the receipt, retention and treatment of:
 - complaints received by the Corporation regarding accounting, internal accounting controls or auditing matters; and
 - confidential, anonymous submission by employees of the Corporation of concerns regarding questionable accounting, internal accounting controls or auditing matters.
- provide oversight to related party transactions entered into by the Corporation.

Independent Auditors

- recommend to the Board for approval by shareholders, the selection, appointment and compensation of the Independent Auditors;
- be directly responsible for oversight of the Independent Auditors and the Independent Auditors shall report directly to the Committee.
- ensure the lead audit partner and the other audit partners (if any) at the Independent Auditor is replaced in compliance with applicable laws.
- be directly responsible for overseeing the work of the Independent Auditors, including the resolution of disagreements between management and the Independent Auditors regarding financial reporting.
- with reference to the procedures outlined separately in "*Procedures for Approval of Non-Audit Services*" (attached hereto as Appendix 'A'), pre-approve all audit and non-audit services not prohibited by law to be provided by the Independent Auditors.
- monitor and assess the relationship between management and the Independent Auditors and monitor, confirm, support and assure the independence and objectivity of the Independent Auditors.
- review the Independent Auditors' audit plan, including scope, procedures, timing and staffing of the audit.
- review the results of the annual audit with the Independent Auditors, including matters related to the conduct of the audit, and receive and review the auditor's interim review reports.
- obtain timely reports from the Independent Auditors describing critical accounting policies and practices, alternative treatments of information within applicable Accounting Principles that were discussed with management, their ramifications, and the Independent Auditors' preferred treatment and material written communications between the Corporation and the Independent Auditors.

- review fees paid by the Corporation to the Independent Auditors and other professionals in respect of audit and non-audit services on an annual basis.
- review and approve the Corporation's hiring policies regarding partners, employees and former partners and employees of the present and former auditors of the Corporation.

Other Responsibilities

- perform any other activities consistent with this Charter and governing law, as the Committee or the Board deems necessary or appropriate;
- institute and oversee special investigations, as needed; and
- review and assess the adequacy of this Charter annually and submit any proposed revisions to the Board for approval.

Procedures for Approval of Non-Audit Services

1. The external auditors to Blueberries Medical Corp. (the “**Corporation**”) shall be prohibited from performing for the Corporation the following categories of non-audit services:

- (a) bookkeeping or other services related to the Corporation’s accounting records or financial statements;
- (b) financial information systems design and implementation;
- (c) appraisal or valuation services, fairness opinion or contributions-in-kind reports;
- (d) actuarial services;
- (e) internal audit outsourcing services;
- (f) management functions;
- (g) human resources;
- (h) broker or dealer, investment adviser or investment banking services;
- (i) legal services;
- (j) expert services unrelated to the audit; and
- (k) any other service that the Canadian Public Accountability Board or any other applicable regulatory authority determines is impermissible.

2. In the event that the Corporation wishes to retain the services of the Corporation’s external auditors for minimal non-audit services (e.g. tax compliance, tax advice or tax planning), the Chief Financial Officer of the Corporation shall consult with the Chair of the Audit Committee of the Board of Directors (the “**Committee**”), who shall have the authority to approve or disapprove on behalf of the Committee, such non-audit services in accordance with the requirements set forth under the “Exemption for minimal non-audit services” provided by Section 2.3 (4) of National Instrument 52-110 - Audit Committees, whereby

- (l) the aggregate fees paid for all the non-audit services that are not approved by the Committee is reasonably expected to constitute no more than five per cent of the aggregate fees paid by the Corporation and its subsidiary entities to the Corporation’s external auditor during the financial year in which the services are provided;
- (m) the Corporation or the subsidiary entity of the issuer, as the case may be, did not recognize the services as non-audit services at the time of the engagement; and
- (n) once recognized as non-audit services, the services are promptly brought to the attention of the Committee of the issuer and approved, prior to the completion of the audit, by the Committee.

3. All other non-audit services shall be approved or disapproved by the Committee as a whole as set forth herein.

4. The Chief Financial Officer of the Corporation shall maintain a record of non-audit services approved by the Chair of the Committee or the Committee for each fiscal year and provide a report to the Committee no less frequently than on a quarterly basis.